Author
@VistaPResearch VistaPResearch
Institutional headline-and-price relay broadcasting article links across a vast cashtag basket
Vista Partners LLC auto-publishes article headlines and intr
trader score
·
hit rate
·
mean α
·
signals 14d
86
Grade = how their written analysis reads (A best). Trader score = how their last-20 timestamped calls performed vs SPY.
Their picks, scored
Not yet in the scored-bets universe (fewer than 20 scoreable calls). Their last-14d mentions, direction-adjusted, have moved -7.2% since posting (mean over 62 mentions with price data).
Recent signals15receipts included
| date (PT) | ticker | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|---|
| 2026-10-16 | EPRX | @VistaPResearch | +0.00 | Briefly describes the disease targeted by Eupraxia; linked context is needed for significance. | +3.8% | tweet ↗ |
| 2026-10-16 | MODD | @VistaPResearch | +0.45 | Frames Modular Medical's Pivot launch and path to revenue as an emerging bullish story. | · | tweet ↗ |
| 2026-10-15 | EPRX | @VistaPResearch | +0.30 | Eupraxia reports reaching the RESOLVE trial enrollment target for EP-104GI. | +1.5% | tweet ↗ |
| 2026-10-13 | PWR | @VistaPResearch | +0.40 | Frames grid constraints as a catalyst for a basket of AI power-infrastructure stocks. | -20.7% | tweet ↗ |
| 2026-10-13 | ETN | @VistaPResearch | +0.40 | Frames grid constraints as a catalyst for a basket of AI power-infrastructure stocks. | -14.5% | tweet ↗ |
| 2026-10-13 | VRT | @VistaPResearch | +0.40 | Frames grid constraints as a catalyst for a basket of AI power-infrastructure stocks. | -18.1% | tweet ↗ |
| 2026-10-13 | GEV | @VistaPResearch | +0.40 | Frames grid constraints as a catalyst for a basket of AI power-infrastructure stocks. | -18.8% | tweet ↗ |
| 2026-10-13 | NVDA | @VistaPResearch | +0.20 | Frames grid constraints as a catalyst for a basket of AI power-infrastructure stocks. | -7.7% | tweet ↗ |
| 2026-10-13 | NVDA | @VistaPResearch | -0.25 | Market recap says chip weakness and inflation risk pressured stocks; only NVDA is directly tied to that claim. | -7.7% | tweet ↗ |
| 2026-10-12 | EPRX | @VistaPResearch | +0.05 | Eupraxia announces presentations at two named medical conferences on Oct. 9–14. | -6.1% | tweet ↗ |
| 2026-10-10 | MRNA | @VistaPResearch | +0.40 | Reports rallies in Moderna and Novavax tied to cancer-vaccine investor confidence. | -11.1% | tweet ↗ |
| 2026-10-10 | NVAX | @VistaPResearch | +0.40 | Reports rallies in Moderna and Novavax tied to cancer-vaccine investor confidence. | -23.9% | tweet ↗ |
| 2026-10-09 | · | @VistaPResearch | · | Weekly summary says stocks closed higher as AI rebounded and consumer sentiment weakened. | · | tweet ↗ |
| 2026-10-08 | · | @VistaPResearch | · | Reports Nasdaq falling 1.25% due to oil and rate concerns. | · | tweet ↗ |
| 2026-10-08 | SPY | @VistaPResearch | +0.30 | Frames Tom Lee's predicted inflation drop as potentially profitable for investors. | -1.8% | tweet ↗ |
Grade is our human read-worthiness rating; trader score is a rolling 20-bet hit-rate/alpha composite — different things, often disagreeing. “Since then” is direction-unaware in the table; the summary line above adjusts for which way they leaned.